+ Watch OMER
on My Watchlist
Q! 2013 NDA filing and mid 2013 filing in europe, looking very postive and phase 3 results exceeded expectations.
I believe OMER will outperform the S&P 500 by a considerable amount. I encourage Fools to go to its website and read about recent developments in its propieteray medical programs. That is a 15 minute task and well worth one's time. OMER has no income at this time, but expects approval of two drugs in 2013, one for arthroscopic knee surgery and a second for eye surgery. Daily trading volume has been small, however, and this should be considered by prospective investors.
G Protein Coupled Receptor cells in portfolio are potentially worth far more than current market value of the company. These are new intellectual properties that add to the value of the drugs in clinical trials. Can be volatile, but long term outlook is good.
this a warning for all beginners! why? so you can put the money in my stocks and so drive my winnings
The patents this company holds are incredible. The breakthrough in patient treatment for pain post-surgery (in clinical trials) is outstanding for arthro, eye, uro, etc. are oustanding. Once any of the trials, in various phases now, hits, this will blow sky high.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions